Earnings summaries and quarterly performance for Jade Biosciences.
Executive leadership at Jade Biosciences.
Board of directors at Jade Biosciences.
Research analysts covering Jade Biosciences.
Recent press releases and 8-K filings for JBIO.
Jade Management Discusses Clinical Pipeline and IgA Nephropathy Market
JBIO
New Projects/Investments
Product Launch
Guidance Update
- Jade (JBIO), founded in June 2024, is developing three assets, with its lead program, JADE101 (anti-APRIL for IgA nephropathy), having initiated a Phase I study in August 2025 and expecting a key readout in H1 2026.
- The company's pipeline includes JADE201 (targeting BAFF-R) anticipated to enter the clinic in H1 2026, and a third undisclosed program in H1 2027.
- Jade is well-resourced to fund all trials into H1 2028.
- Management views IgA nephropathy as a a $10 billion+ opportunity in the US alone, emphasizing the disease-modifying potential of anti-APRIL therapies and the importance of convenience through infrequent dosing for JADE101.
- The FDA is considering shortening eGFR confirmatory trials for iGAN from two years to one year, which could support efficient development of anti-APRIL mechanisms.
Nov 17, 2025, 3:30 PM
JBIO Provides Update on Autoimmune Pipeline and IgA Nephropathy Market at Jefferies Conference
JBIO
New Projects/Investments
Product Launch
- JBIO, founded in June 2024, is developing best-in-class therapeutics for autoimmune diseases, with its lead program, JADE101, an anti-APRIL for IgA nephropathy (iGAN).
- The company initiated a Phase I healthy volunteer study for JADE101 in August 2025, with a key readout anticipated in the first half of 2026.
- JADE101 targets the iGAN market, estimated at over $10 billion in the US alone, and aims for best-in-class convenience with infrequent dosing.
- JBIO is well-resourced to fund its three pipeline programs into the first half of 2028.
- The second program, JADE201 (targeting BAFF-R), is expected to enter the clinic in the first half of 2026, with a third undisclosed program planned for the first half of 2027.
Nov 17, 2025, 3:30 PM
Jade Biosciences Reports Q3 2025 Financial Results and Corporate Updates
JBIO
Earnings
New Projects/Investments
- Jade Biosciences reported a net loss of $25.2 million for the third quarter ended September 30, 2025, compared to a net loss of $16.3 million for the same period in 2024.
- Research and Development (R&D) expenses increased to $22.0 million in Q3 2025 from $13.6 million in Q3 2024, while General and Administrative (G&A) expenses rose to $5.4 million from $1.4 million over the same periods.
- The company completed a $135 million private placement, which is expected to extend its cash runway into the first half of 2028.
- Significant pipeline progress includes the initiation of a Phase 1 healthy volunteer study for JADE101, with interim data anticipated in the first half of 2026, and the unveiling of JADE201, with its first-in-human trial expected to commence in the first half of 2026.
- As of September 30, 2025, Jade Biosciences held $198.9 million in cash, cash equivalents, and investments.
Nov 14, 2025, 12:00 PM
Jade Biosciences Updates on Pipeline Progress and Financial Position
JBIO
New Projects/Investments
Guidance Update
Convertible Preferred Issuance
- Jade Biosciences reported a pro forma cash position of $326 million as of October 2025, providing a financial runway into 1H 2028.
- The company is advancing three key programs: JADE101 (anti-APRIL for IgAN) with interim data expected in 1H 2026, JADE201 (anti-BAFF-R for autoimmune diseases) with planned First-in-Human (FIH) in 1H 2026, and JADE-003 (undisclosed) with planned FIH in 1H 2027.
- JADE101 targets the IgA nephropathy (IgAN) market, estimated at over $10 billion in the U.S. alone, and is designed for superior potency, extended half-life, and infrequent dosing.
- As of October 6, 2025, Jade Biosciences had 67,394,380 total outstanding shares, including common stock, preferred stock (as converted), and pre-funded warrants.
Nov 13, 2025, 11:00 PM
Jade Biosciences Discusses Lead Asset Jade 101 Development and Recent Financings
JBIO
New Projects/Investments
Debt Issuance
Convertible Preferred Issuance
- Jade Biosciences, founded last year, is developing Jade 101, an anti-APRIL therapeutic for IgA nephropathy (IgAN), targeting a Q8-week dosing interval or potentially longer.
- The company anticipates releasing Phase 1 healthy volunteer data for Jade 101 in the first half of 2026, with a focus on achieving maximal APRIL and IgA reductions.
- Jade Biosciences completed a reverse merger in April 2025, which included a $200 million PIPE and a $95 million convertible note, and subsequently closed an additional $135 million financing in October 2025.
- The FDA is exploring alternative, more efficient development pathways for IgAN therapies, which could potentially streamline Jade 101's path to market.
Nov 13, 2025, 8:00 PM
Jade Biosciences Secures Financing and Advances Autoimmune Therapies
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences has secured $135 million in additional gross proceeds, which is expected to support its cash runway into H1 2028.
- The company is advancing JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy (IgAN), with interim clinical data from its Phase 1 healthy volunteer trial anticipated in H1 2026. JADE101 is designed for high potency and infrequent dosing, targeting an estimated $10B+ branded market in the U.S. alone for IgAN.
- Jade's pipeline also includes JADE201, an anti-BAFF-R mAb with planned First-in-Human (FIH) studies in H1 2026 for multiple systemic autoimmune diseases, and JADE-003 with planned FIH in H1 2027.
- As of October 6, 2025, Jade Biosciences reported 67,394,380 total outstanding shares.
Nov 12, 2025, 11:00 PM
Jade Biosciences Provides Update on Pipeline Progress and Financial Position
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences, formed in June 2024, is focused on developing therapies for autoimmune diseases, with its lead program, JADE101 (an anti-APRIL for IgA nephropathy), having initiated a Phase I study with readout anticipated in the first half of 2025.
- The company's second program, JADE201 (a BAFF receptor antibody), is slated to begin its first trial in rheumatoid arthritis patients in the first half of next year.
- Jade Biosciences secured $300 million in April 2024 via a reverse merger and an additional $135 million from a PIPE in October 2024, extending its cash runway into the first half of 2028.
- JADE101 is designed for ultra-high binding affinity to APRIL and half-life extension, aiming for a convenient dosing schedule of no more than one injection every eight weeks.
Nov 12, 2025, 9:00 PM
Jade Biosciences Secures $135 Million Private Financing and Outlines Pipeline Advancement
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences announced a private financing of approximately $135 million in gross proceeds, which is expected to fund operations into 2028.
- The financing will support the clinical development of JADE one zero one, currently in Phase 1, with interim biomarker data anticipated in 2026, and its progression into late-stage IgAN patient trials.
- Funds will also advance JADE two zero one, a half-life extended monoclonal antibody targeting BAFR with a total addressable market of over $80 billion, into its first-in-human study in rheumatoid arthritis patients in 2026.
Oct 7, 2025, 12:00 PM
Jade Biosciences Provides Pipeline Update and Extends Cash Runway
JBIO
New Projects/Investments
Guidance Update
- Jade Biosciences has secured $135 million in additional financing, which is expected to support its cash runway into H1 2028.
- The company is advancing its pipeline of therapies for autoimmune diseases, including JADE101, JADE201, and JADE-003.
- The JADE201 program, an anti-BAFF-R antibody, is slated to begin its First-in-Human trial in H1 2026 for rheumatoid arthritis patients.
- Preclinical data for JADE201 indicate a differentiated profile with >2X half-life extension in NHPs compared to ianalumab, suggesting potential for best-in-class efficacy and infrequent dosing across a broad range of autoimmune indications with an addressable market of over $80 billion.
Oct 7, 2025, 12:00 PM
Jade Biosciences Announces $135 Million Private Placement
JBIO
New Projects/Investments
- Jade Biosciences announced a $135 million private placement (PIPE) financing.
- The financing included the sale of 13,368,164 shares of common stock at $9.14 per share and 1,402,092 pre-funded warrants at $9.1399 per pre-funded warrant.
- The company expects the net proceeds, combined with existing cash, to fund operations into the first half of 2028.
- Following the transaction, there will be approximately 67.4 million shares of Common Stock and Common Stock equivalents issued and outstanding on a pro forma basis.
- Key investors participating in the PIPE include Janus Henderson Investors, Fairmount, RA Capital Management, Marshall Wace, Aberdeen Investments, Great Point Partners, LLC, Venrock Healthcare Capital Partners, Samsara BioCapital, and Avidity Partners.
Oct 7, 2025, 11:13 AM
Quarterly earnings call transcripts for Jade Biosciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track Jade Biosciences's earnings for you
Get instant analysis when filings drop